Beaumont is the first hospital in Michigan to implant the commercially approved MitraClip to help high-risk patients with degenerative mitral valve regurgitation. Mitral valve regurgitation is the most common form of heart valve disease with an estimated 4 million people in the U.S. having significant mitral valve regurgitation.
“The MitraClip gives us the opportunity to help patients with severe mitral valve regurgitation that in the past did not have any options,” stated George Hanzel, M.D., Director of Cardiac Catheterization Laboratories at Beaumont, Royal Oak.
Dr. Robert Safian, Director of the Center for Innovation and Research in Cardiovascular Diseases, added, “Beaumont’s Center for Innovation and Research in Cardiovascular Diseases offers the most innovative therapies to our patients, many of whom have been searching for treatment options. The availability of MitraClip allows us to treat patients who are too high risk for surgery and have no other options for treatment, with minimal risk.”
The FDA approved the use of the MitraClip in October 2013 to treat high-risk patients with degenerative mitral valve regurgitation. Surgery is typically not an option for these patients because of the severity of their condition.
In 2008, Beaumont was the first hospital in Metro Detroit to treat patients in a clinical study evaluating the MitraClip system to repair the mitral valve without heart surgery.